1 research outputs found
Tea Polyphenol Epigallocatechin Gallate Protects Against Nonalcoholic Fatty Liver Disease and Associated Endotoxemia in Rats via Modulating Gut Microbiota Dysbiosis and Alleviating Intestinal Barrier Dysfunction and Related Inflammation
Nonalcoholic
fatty liver disease (NAFLD) is characterized
by fat
accumulation and inflammation. Epigallocatechin gallate (EGCG) has
been proven to be effective against NAFLD, but its hepatoprotective
mechanisms based on the “gut microbiota-barrier-liver axis”
are still not fully understood. Herein, the results demonstrated that
EGCG effectively ameliorated NAFLD phenotypes and metabolic disorders
in rats fed a high-fat diet (HFD), and inhibited intestinal barrier
dysfunction and inflammation, which is also supported in the experiment
of Caco-2 cells. Moreover, EGCG could restore gut microbiota diversity
and composition, particularly promoting beneficial microbes, including
short-chain fatty acids (SCFAs) producers, such as Lactobacillus, and suppressing Gram-negative bacteria,
such as Desulfovibrio. The microbial
modulation raised SCFA levels, decreased lipopolysaccharide levels,
inhibited the TLR4/NF-ÎşB pathway, and strengthened intestinal
barrier function via Nrf2 pathway activation, thereby alleviating
liver steatosis and inflammation. Spearman’s correlation analysis
showed that 24 key OTUs, negatively or positively associated with
NAFLD and metabolic disorders, were also reshaped by EGCG. Our results
suggested that a combinative improvement of EGCG on gut microbiota
dysbiosis, intestinal barrier dysfunction, and inflammation might
be a potential therapeutic target for NAFLD